Editas Medicine (EDIT) Advancing Gene Editing Amid Struggles
Wasim Omar
September 6, 2024
Editas Medicine, Inc. (NASDAQ: EDIT) is a clinical-stage company specializing in genome editing, with a focus on developing transformative treatments for serious diseases. The company’s